Show simple item record

dc.contributor.authorGeorge, A
dc.contributor.authorKristeleit, R
dc.contributor.authorRafii, S
dc.contributor.authorMichie, CO
dc.contributor.authorBowen, R
dc.contributor.authorMichalarea, V
dc.contributor.authorvan Hagen, T
dc.contributor.authorWong, M
dc.contributor.authorRallis, G
dc.contributor.authorMolife, LR
dc.contributor.authorLopez, J
dc.contributor.authorBanerji, U
dc.contributor.authorBanerjee, SN
dc.contributor.authorGore, ME
dc.contributor.authorde Bono, JS
dc.contributor.authorKaye, SB
dc.contributor.authorYap, TA
dc.date.accessioned2017-05-03T14:30:40Z
dc.date.issued2017-05-01
dc.identifier.citationEuropean journal of cancer (Oxford, England : 1990), 2017, 76 pp. 52 - 59
dc.identifier.issn0959-8049
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/632
dc.identifier.eissn1879-0852
dc.identifier.doi10.1016/j.ejca.2017.01.020
dc.description.abstractDrug resistance to conventional anticancer therapies is almost inevitable in patients with advanced ovarian cancer (AOC), limiting their available treatment options. Novel phase I trial therapies within a dedicated drug development unit may represent a viable alternative; however, there is currently little evidence for patient outcomes in such patients. To address this, we undertook a retrospective review of patients with AOC allocated to phase I trials in the Drug Development Unit at Royal Marsden Hospital (RMH) between June 1998 and October 2010. A total of 200 AOC patients with progressive disease were allocated to ≥1 trial each, with a total of 281 allocations. Of these, 135 (68%) patients commenced ≥1 trial (mean 1.4 [1-8]), totaling 216 allocated trials; 65 (32%) patients did not start due to deterioration resulting from rapidly progressive disease (63 patients) or patient choice (2 patients). Response Evaluation Criteria in Solid Tumours (RECIST) complete/partial responses (CR/PR) were observed in 43 (20%) of those starting trials, including those on poly(ADP-ribose) polymerase (PARP) inhibitors (18/79 [23%]), antiangiogenics (9/65 [14%]) and chemotherapy combinations (14/43 [33%]). Factors associated with CR/PR included: fewer prior treatments, platinum-sensitive disease, CR/PR with prior therapy, (the United States-based) Eastern Cooperative Oncology Group (ECOG) performance status score, fewer metastatic sites, higher albumin and haemoglobin levels, lower white cell counts and baseline CA125 levels, germline BRCA1/2 mutations and better RMH Prognostic Score. Mean survival was 32° months for patients who achieved CR/PR. Treatments were generally well tolerated. Most patients with AOC (134/200 [67%]) received ≥1 subsequent line of therapy after phase I trials. Our data suggest that phase I trial referrals should be considered earlier in the AOC treatment pathway and before the onset of rapid disease progression particularly with the emergence of promising novel agents in the era of precision medicine.
dc.formatPrint-Electronic
dc.format.extent52 - 59
dc.languageeng
dc.language.isoeng
dc.publisherELSEVIER SCI LTD
dc.rights.urihttps://www.rioxx.net/licenses/all-rights-reserved
dc.subjectHumans
dc.subjectCarcinosarcoma
dc.subjectAdenocarcinoma, Clear Cell
dc.subjectCarcinoma, Endometrioid
dc.subjectNeoplasms, Cystic, Mucinous, and Serous
dc.subjectGranulosa Cell Tumor
dc.subjectOvarian Neoplasms
dc.subjectNeoplasm Metastasis
dc.subjectSerum Albumin
dc.subjectHemoglobins
dc.subjectMembrane Proteins
dc.subjectAntineoplastic Agents
dc.subjectCA-125 Antigen
dc.subjectLeukocyte Count
dc.subjectPrognosis
dc.subjectTreatment Outcome
dc.subjectSeverity of Illness Index
dc.subjectSurvival Rate
dc.subjectRetrospective Studies
dc.subjectGenes, BRCA1
dc.subjectGenes, BRCA2
dc.subjectAdult
dc.subjectAged
dc.subjectMiddle Aged
dc.subjectEngland
dc.subjectFemale
dc.subjectClinical Trials, Phase I as Topic
dc.subjectDrug Discovery
dc.subjectHereditary Breast and Ovarian Cancer Syndrome
dc.titleClinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trials.
dc.typeJournal Article
dcterms.dateAccepted2017-01-25
rioxxterms.versionofrecord10.1016/j.ejca.2017.01.020
rioxxterms.licenseref.urihttps://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2017-05
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfEuropean journal of cancer (Oxford, England : 1990)
pubs.notesNo embargo
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicine (de Bono Prostate)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicine Drug Development Unit (de Bono)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Pharmacology – Adaptive Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine Drug Development Unit (de Bono)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Medicine Drug Development Unit (Kaye)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicine (de Bono Prostate)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicine Drug Development Unit (de Bono)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Pharmacology – Adaptive Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine Drug Development Unit (de Bono)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Medicine Drug Development Unit (Kaye)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume76
pubs.embargo.termsNo embargo
icr.researchteamMedicine (de Bono Prostate)
icr.researchteamClinical Pharmacology – Adaptive Therapy
icr.researchteamMedicine Drug Development Unit (de Bono)
icr.researchteamProstate Cancer Targeted Therapy Group
icr.researchteamMedicine Drug Development Unit (Kaye)
dc.contributor.icrauthorBanerji, Udai


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record